Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Monopar Therapeutics Inc (NASDAQ: MNPR) closed at $68.63 in the last session, up 4.00% from day before closing price of $65.99. In other words, the price has increased by $4.00 from its previous closing price. On the day, 0.52 million shares were traded. MNPR stock price reached its highest trading level at $70.11 during the session, while it also had its lowest trading level at $65.77.
Ratios:
We take a closer look at MNPR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 56.10 and its Current Ratio is at 56.10. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 10, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $115. On October 13, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $125.Barclays initiated its Overweight rating on October 13, 2025, with a $125 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 18 ’25 when Arthur Klausner bought 5,121 shares for $67.16 per share.
KLAUSNER ARTHUR J sold 5,121 shares of MNPR for $343,889 on Dec 18 ’25. The Director now owns 8,762 shares after completing the transaction at $67.15 per share. On Sep 24 ’25, another insider, Tactic Pharma LLC, who serves as the 10% Owner of the company, sold 550,229 shares for $63.61 each. As a result, the insider received 34,999,957 and left with 272,026 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MNPR now has a Market Capitalization of 458625728 and an Enterprise Value of 315052192.
Stock Price History:
The Beta on a monthly basis for MNPR is 1.50, which has changed by 1.8595834 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, MNPR has reached a high of $105.00, while it has fallen to a 52-week low of $21.00. The 50-Day Moving Average of the stock is -15.76%, while the 200-Day Moving Average is calculated to be 31.17%.
Shares Statistics:
According to the various share statistics, MNPR traded on average about 133.99K shares per day over the past 3-months and 224780 shares per day over the past 10 days. A total of 6.66M shares are outstanding, with a floating share count of 4.55M. Insiders hold about 32.50% of the company’s shares, while institutions hold 57.96% stake in the company. Shares short for MNPR as of 1764288000 were 507439 with a Short Ratio of 3.79, compared to 1761868800 on 256778. Therefore, it implies a Short% of Shares Outstanding of 507439 and a Short% of Float of 20.28.
Earnings Estimates
. The current rating of Monopar Therapeutics Inc (MNPR) reflects the combined expertise of 9.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.39 and low estimates of -$1.73.
Analysts are recommending an EPS of between -$1.58 and -$1.84 for the fiscal current year, implying an average EPS of -$1.68. EPS for the following year is -$3.45, with 10.0 analysts recommending between -$1.53 and -$6.91.
